Anti-cancer potential of substituted “amino-alkyl-rhodamine” derivatives against MCF-7 human breast cancer cell line

Abstract

Breast cancer is the most prevalent diagnosed cancer among women and the main cause of morbidity and mortality. As for breast cancer, MCF-7 cells are an important candidate since they are widely utilised in research for oestrogen receptor (ER)-positive breast cancer cell assays, and various sub-clones have been identi ed to re ect different classes of ER-positive tumours with varied levels of nuclear receptor expression. Rhodamines and its derivatives have shown a great interest over the past two decades due to their excellent structural and spectroscopic properties. Rhodamine derivatives have been widely investigated for their mitochondrial targeting and chemotherapeutic properties. Rhodamine derivatives, in particular, have been widely investigated for their therapeutic properties. In this regard, several studies have shown that Rhodamine dye derivatives have promising in vitro and in vivo therapeutic e cacy. The present study deals with potential anticancer activity of few synthesized rhodamine derivatives against MCF-7 cell lines.

Rhodamine B Amide Derivatives with Anticancer Activity and Fluorescence Properties for Potential Theranostic Applications

“…Bis-(aminoethyl)-piperazinyl substituted rhodamine derivative displayed the highest activity against the MCF-7 cell line, specifying À 42.1 % control growth at 10 μg/mL of the positive control, Adriamycin (ADR); nonetheless, photophysical properties and bio-imaging applications were not explored. [16] On a similar rationale, another complex structure of RHB (rhodamine B 6-[3-(2-methoxy-5methylphenylcarbamoyloxy)-9-azabicyclo[3.3.1]nonane-9yl]hexylamide) synthesized was utilized in the diagnosis of breast cancer. [17] Hitherto, several dyes developed and promoted for diverse biomedical applications abide by high toxicity, low quantum yields, and low bio-compatibility.…”

“…Bag's group reported anticancer activity of spirocyclic amino ethyl rhodamine derivatives against MCF‐7 cell lines; revealing amino‐piperazine and nitro‐aromatic substituted rhodamine derivatives as potential anticancer agents, by structure‐function correlation. Bis‐(aminoethyl)‐piperazinyl substituted rhodamine derivative displayed the highest activity against the MCF‐7 cell line, specifying −42.1 % control growth at 10 μg/mL of the positive control, Adriamycin (ADR); nonetheless, photophysical properties and bio‐imaging applications were not explored [16] . On a similar rationale, another complex structure of RHB (rhodamine B 6‐[3‐(2‐methoxy‐5‐methylphenylcarbamoyloxy)‐9‐azabicyclo[3.3.1]nonane‐9‐yl]hexylamide) synthesized was utilized in the diagnosis of breast cancer [17]…”